ISRCTN58800347已完成未知
Tolerability of the intravenous immunoglobulin Octagam® 10%
Octapharma GmbH (Germany)0 个研究点目标入组 600 人开始时间: 2008年12月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29020871 post-authorisation safety analysis 2018 Results article in https://pubmed.ncbi.nlm.nih.gov/29517417/ (added 14/11/2022)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •Patients of any age and gender who receive treatment with Octagam® 10%
排除标准
- •Patients with known contraindications to Octagam® 10%
研究者
相似试验
已完成
2 期
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITPPurpura, Thrombocytopenic, IdiopathicNCT00220727Grifols Therapeutics LLC8
已完成
2 期
Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar AtaxiaSpinocerebellar AtaxiaNCT01350440University of South Florida5
已完成
3 期
Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency PatientsSevere Combined ImmunodeficiencyImmunologic Deficiency SyndromeAgammaglobulinemiaWiskott-Aldrich SyndromeCommon Variable ImmunodeficiencyNCT00220766Grifols Therapeutics LLC100
已完成
3 期
Pharmacokinetics and Safety of IVIG Nanogam 100 mg/mlPrimary ImmunodeficiencyNCT01985373Prothya Biosolutions23
进行中（未招募）
3 期
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral ImmunodeficiencyPrimary Immune DeficiencyNCT04565015GC Biopharma Corp24